2024 | 2023 | 2022| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | 2011 | 2008 | 2006 | 2005 | 2003 | 2002

Selected Publications

Ganguly S, Lone Z, Muskara A, Imamura J, Hardaway A, Patel M, Berk M, Smile TD, Davicioni E, Stephans KL, Ciezki J, Weight CJ, Gupta S, Reddy CA, Tendulkar RD, Chakraborty AA, Klein EA, Sharifi N, Mian OY. Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer. J Clin Invest. 2023 Nov 15;133(22):e165718. doi: 10.1172/JCI165718. PMID: 37966114; PMCID: PMC10645386.

Lotan Y, de Jong JJ, Liu VYT, Bismar TA, Boorjian SA, Huang HC, Davicioni E, Mian OY, Wright JL, Necchi A, Dall'Era MA, Kaimakliotis HZ, Black PC, Gibb EA, Boormans JL. Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. J Urol. 2022 Mar;207(3):541-550. doi: 10.1097/JU.0000000000002261. Epub 2021 Oct 13. PMID: 34643090.

Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clin Cancer Res. 2019 Jan 1;25(1):210-221. doi: 10.1158/1078-0432.CCR-18-1278. Epub 2018 Oct 16. PMID: 30327311; PMCID: PMC6333466.

Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC. Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clin Cancer Res. 2019 Jul 1;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558. Epub 2019 Apr 5. PMID: 30952638.

Hedayati M, Haffner MC, Coulter JB, Raval RR, Zhang Y, Zhou H, Mian O, Knight EJ, Razavi N, Dalrymple S, Isaacs JT, Santos A, Hales R, Nelson WG, Yegnasubramanian S, DeWeese TL. Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation. Clin Cancer Res. 2016 Jul 1;22(13):3310-3319. doi: 10.1158/1078-0432.CCR-15-1147. Epub 2016 Feb 1. PMID: 26831716; PMCID: PMC4930695.

Mian OY, Khattab MH, Hedayati M, Coulter J, Abubaker-Sharif B, Schwaninger JM, Veeraswamy RK, Brooks JD, Hopkins L, Shinohara DB, Cornblatt B, Nelson WG, Yegnasubramanian S, DeWeese TL. GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. Prostate. 2016 Feb;76(2):199-206. doi: 10.1002/pros.23111. Epub 2015 Oct 8. PMID: 26447830; PMCID: PMC4734373.

2024

Reike MJ, de Jong JJ, Bismar TA, Boorjian SA, Mian OY, Wright JL, Dall'Era MA, Kaimakliotis HZ, Lotan Y, Boormans JL, Black PC, Gibb EA. Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers. Urol Oncol. 2024 Jun;42(6):177.e5-177.e14. doi: 10.1016/j.urolonc.2024.01.027. Epub 2024 Mar 12. PubMed PMID: 38480079.

Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 May;22(4):216-225. doi: 10.6004/jnccn.2024.0024. PubMed PMID: 38754471.

Buyyounouski MK, Pugh SL, Chen RC, Mann MJ, Kudchadker RJ, Konski AA, Mian OY, Michalski JM, Vigneault E, Valicenti RK, Barkati M, Lawton CAF, Potters L, Monitto DC, Kittel JA, Schroeder TM, Hannan R, Duncan CE, Rodgers JP, Feng F, Sandler HM. Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 May 1;10(5):584-591. doi: 10.1001/jamaoncol.2023.7291. PubMed PMID: 38483412; PubMed Central PMCID: PMC10941019.

Taghizadeh S, Shvydka D, Shan A, Mian OY, Parsai EI. Optimization and experimental characterization of the innovative thermo-brachytherapy seed for prostate cancer treatment. Med Phys. 2024 Feb;51(2):839-853. doi: 10.1002/mp.16920. Epub 2023 Dec 30. PubMed PMID: 38159297.

Liao RS, Ruan HT, Jang A, Huynh M, Nadal Rios R, Hoffman-Censits JH, Wei S, Mian OY, Barata PC. Emerging Insights in Small-Cell Carcinoma of the Genitourinary Tract: From Diagnosis to Novel Therapeutic Horizons. Am Soc Clin Oncol Educ Book. 2024 Jan;44:e430336. doi: 10.1200/EDBK_430336. Review. PubMed PMID: 38176691.

Mian OY, Tendulkar RD. Withdraw or Deposit?. Int J Radiat Oncol Biol Phys. 2024 Jan 1;118(1):12-13. doi: 10.1016/j.ijrobp.2023.10.042. PubMed PMID: 38049220. 

2023

Jang A, Lanka SM, Ruan HT, Kumar HLS, Jia AY, Garcia JA, Mian OY, Barata PC. Novel therapies for metastatic prostate cancer. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(12):1251-1263. doi: 10.1080/14737140.2023.2290197. Epub 2023 Dec 8. Review. PubMed PMID: 38030394.

Ganguly S, Lone Z, Muskara A, Imamura J, Hardaway A, Patel M, Berk M, Smile TD, Davicioni E, Stephans KL, Ciezki J, Weight CJ, Gupta S, Reddy CA, Tendulkar RD, Chakraborty AA, Klein EA, Sharifi N, Mian OY. Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer. J Clin Invest. 2023 Nov 15;133(22). doi: 10.1172/JCI165718. PubMed PMID: 37966114; PubMed Central PMCID: PMC10645386.

Guo B, Stephans K, Godley A, Kolar M, Magnelli A, Tendulkar R, Mian O, Majkszak D, Xia P. Transperineal ultrasound is a good alternative for intra-fraction motion monitoring for prostate stereotactic body radiotherapy. J Appl Clin Med Phys. 2023 Oct;24(10):e14021. doi: 10.1002/acm2.14021. Epub 2023 May 5. PubMed PMID: 37144947; PubMed Central PMCID: PMC10562017.

Mayo ZS, Parker SM, Kilic SS, Weleff J, Phelan M, Mian OY, Stephans KL, Suh JH, Tendulkar RD. Disparities in Prostate Cancer Diagnoses Among Persons Experiencing Homelessness. Eur Urol. 2023 Jul;84(1):144-145. doi: 10.1016/j.eururo.2023.03.024. Epub 2023 Apr 6. PubMed PMID: 37031006.

Imamura J, Ganguly S, Muskara A, Liao RS, Nguyen JK, Weight C, Wee CE, Gupta S, Mian OY. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution. Front Endocrinol (Lausanne). 2023;14:1191311. doi: 10.3389/fendo.2023.1191311. eCollection 2023. Review. PubMed PMID: 37455903; PubMed Central PMCID: PMC10349394.

Benidir T, Lone Z, Nguyen JK, Ward R, Hofmann M, Klein EA, Mian OY, Weight CJ, Purysko AS. The combination of prostate MRI PI-RADS scoring system and a genomic classifier is associated with pelvic lymph node metastasis at the time of radical prostatectomy. Br J Radiol. 2023 Mar 1;96(1144):20220663. doi: 10.1259/bjr.20220663. Epub 2023 Feb 20. PubMed PMID: 36745009; PubMed Central PMCID: PMC10078867.

2022

Elagooz R, Dhara AR, Gott RM, Adams SE, White RA, Ghosh A, Ganguly S, Man Y, Owusu-Ansah A, Mian OY, Gurkan UA, Komar AA, Ramamoorthy M, Gnanapragasam MN. PUM1 mediates the posttranscriptional regulation of human fetal hemoglobin. Blood Adv. 2022 Dec 13;6(23):6016-6022. doi: 10.1182/bloodadvances.2021006730. PubMed PMID: 35667093; PubMed Central PMCID: PMC9699939.

Mayo ZS, Kilic SS, Weleff J, Parker SM, Strzalka C, Phelan M, Mian OY, Stephans KL, Suh JH, Tendulkar RD. Prostate Cancer Screening Disparities in Persons Experiencing Homelessness. JCO Oncol Pract. 2022 Nov;18(11):e1866-e1873. doi: 10.1200/OP.22.00412. Epub 2022 Oct 7. PubMed PMID: 36206501.

Lone Z, Benidir T, Rainey M, Nair M, Davicioni E, Gibb EA, Williamson S, Gupta S, Chaim Ornstein M, Tendulkar R, Weight C, Nguyen JK, Klein EA, Mian OY. Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate. Eur Urol Focus. 2022 Nov;8(6):1575-1582. doi: 10.1016/j.euf.2022.05.005. Epub 2022 May 31. PubMed PMID: 35662504.

Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 Aug;20(8):866-878. doi: 10.6004/jnccn.2022.0041. PubMed PMID: 35948037.

Anderson PM, Trucco MM, Tarapore RS, Zahler S, Thomas S, Gortz J, Mian O, Stoignew M, Prabhu V, Morrow S, Allen JE. Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor. Clin Cancer Res. 2022 May 2;28(9):1773-1782. doi: 10.1158/1078-0432.CCR-21-4030. PubMed PMID: 35022321; PubMed Central PMCID: PMC9306280.

Lotan Y, de Jong JJ, Liu VYT, Bismar TA, Boorjian SA, Huang HC, Davicioni E, Mian OY, Wright JL, Necchi A, Dall'Era MA, Kaimakliotis HZ, Black PC, Gibb EA, Boormans JL. Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. J Urol. 2022 Mar;207(3):541-550. doi: 10.1097/JU.0000000000002261. Epub 2021 Oct 13. PubMed PMID: 34643090.

Guan Y, Hasipek M, Jiang D, Tiwari AD, Grabowski DR, Pagliuca S, Kongkiatkamon S, Patel B, Singh S, Parker Y, LaFramboise T, Lindner D, Sekeres MA, Mian OY, Saunthararajah Y, Maciejewski JP, Jha BK. Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia. J Clin Invest. 2022 Feb 15;132(4). doi: 10.1172/JCI149856. PubMed PMID: 35085104; PubMed Central PMCID: PMC8843742.

Smile TD, Tom MC, Halima A, Ciezki JP, Reddy CA, Stephans KL, Mian OY, Zhang RX, Klein EA, Campbell S, Ulchaker J, Angermeier K K, Tendulkar RD. (125)I Interstitial brachytherapy with or without androgen deprivation therapy among unfavorable-intermediate and high-risk prostate cancer. Brachytherapy. 2022 Jan-Feb;21(1):85-93. doi: 10.1016/j.brachy.2021.09.001. Epub 2021 Oct 14. PubMed PMID: 34656435.

2021

Guan Y, Tiwari AD, Phillips JG, Hasipek M, Grabowski DR, Pagliuca S, Gopal P, Kerr CM, Adema V, Radivoyevitch T, Parker Y, Lindner DJ, Meggendorfer M, Abazeed M, Sekeres MA, Mian OY, Haferlach T, Maciejewski JP, Jha BK. A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms. Blood Cancer Discov. 2021 Mar;2(2):146-161. doi: 10.1158/2643-3230.BCD-20-0173. Epub 2020 Dec 7. PubMed PMID: 33681816; PubMed Central PMCID: PMC7935131.

Dominello MM, Sanders T, Anscher M, Bayouth J, Brock KK, Carlson DJ, Hugo G, Joseph S, Knisely J, Mendonca MS, Mian OY, Moros EG, Singh AK, Yu JB. Responses to the 2018 and 2019 "One Big Discovery" Question: ASTRO Membership's Opinions on the Most Important Research Question Facing Radiation Oncology…Where Are We Headed?. Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):38-40. doi: 10.1016/j.ijrobp.2020.08.032. Epub 2020 Aug 14. PubMed PMID: 32798605.

Ganguly S, Naik D, Muskara A, Mian OY. The Nexus of Endocrine Signaling and Cancer: How Steroid Hormones Influence Genomic Stability. Endocrinology. 2021 Jan 1;162(1). doi: 10.1210/endocr/bqaa177. PubMed PMID: 33260197; PubMed Central PMCID: PMC7707372.

2020

Fallah J, Diaz-Montero CM, Rayman P, Wei W, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Dann P, Company D, Stephenson A, Campbell S, Haber G, Lee B, Mian O, Gilligan T, Garcia JA, Rini B, Ornstein MC, Grivas P. Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. Clin Genitourin Cancer. 2020 Dec;18(6):500-508. doi: 10.1016/j.clgc.2020.03.004. Epub 2020 Mar 19. PubMed PMID: 32340875.

Broughman JR, Vuong W, Mian OY. Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer. Curr Treat Options Oncol. 2020 Nov 23;22(1):3. doi: 10.1007/s11864-020-00800-5. Review. PubMed PMID: 33230599; PubMed Central PMCID: PMC7719006.

Broughman JR, Fleming CW, Mian OY, Stephans KL, Tendulkar RD. Management of Oligometastatic Prostate Cancer. Appl Radiat Oncol. 2020 Sep;9(3):6-10. Epub 2020 Sep 9. PubMed PMID: 33134438; PubMed Central PMCID: PMC7595346.

Vander Velde R, Yoon N, Marusyk V, Durmaz A, Dhawan A, Miroshnychenko D, Lozano-Peral D, Desai B, Balynska O, Poleszhuk J, Kenian L, Teng M, Abazeed M, Mian O, Tan AC, Haura E, Scott J, Marusyk A. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. Nat Commun. 2020 May 14;11(1):2393. doi: 10.1038/s41467-020-16212-w. PubMed PMID: 32409712; PubMed Central PMCID: PMC7224215.

Sheng IY, Diaz-Montero CM, Rayman P, Wei W, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Company D, Stephenson A, Campbell S, Haber G, Lee B, Mian O, Gilligan TD, Rini BI, Garcia JA, Grivas P, Ornstein MC. Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma. Target Oncol. 2020 Apr;15(2):211-220. doi: 10.1007/s11523-020-00707-z. PubMed PMID: 32207064.

Grivas P, Bismar TA, Alva AS, Huang HC, Liu Y, Seiler R, Alimohamed N, Cheng L, Hyndman ME, Dabbas B, Black PC, Davicioni E, Wright JL, Ornstein MC, Mian OY, Kaimakliotis HZ, Gibb EA, Lotan Y. Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. Urol Oncol. 2020 Apr;38(4):262-268. doi: 10.1016/j.urolonc.2019.11.004. Epub 2019 Dec 4. PubMed PMID: 31812633.

Tendulkar RD, Mian OY. Yes, Nodal Recurrence of Prostate Cancer is Potentially Curable. Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):238. doi: 10.1016/j.ijrobp.2019.07.016. PubMed PMID: 31928637.

Tom MC, Reddy CA, Smile TD, Zhang RX, Ciezki JP, Stephans KL, Mian OY, Klein EA, Campbell S, Ulchaker J, Angermeier K, Tendulkar RD. Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy. Brachytherapy. 2020 Jan-Feb;19(1):43-50. doi: 10.1016/j.brachy.2019.10.005. Epub 2019 Dec 5. PubMed PMID: 31813740.

Peng LC, Mian OY, Lakshminarayanan P, Huang P, Bae HJ, Robertson S, Habtu T, Narang A, Agarwal S, Greco S, Tran P, McNutt T, DeWeese TL, Song DY. Analysis of Spatial Dose-Volume Relationships and Decline in Sexual Function Following Permanent Brachytherapy for Prostate Cancer. Urology. 2020 Jan;135:111-116. doi: 10.1016/j.urology.2019.08.014. Epub 2019 Aug 24. PubMed PMID: 31454660.

2019

Ericson KJ, Murthy PB, Bryk DJ, Ramkumar RR, Broughman JR, Khanna A, Mian OY, Campbell SC. Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer. Clin Adv Hematol Oncol. 2019 Dec;17(12):697-707. Review. PubMed PMID: 31851158.

Tom MC, Nguyen JK, Lucianò R, Mian OY, Stephans KL, Ciezki JP, Smile TD, Wei W, McKenney JK, Magi-Galluzzi C, Tendulkar RD. Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy. J Urol. 2019 Oct;202(4):710-716. doi: 10.1097/JU.0000000000000316. Epub 2019 Sep 6. PubMed PMID: 31059665.

Purysko AS, Magi-Galluzzi C, Mian OY, Sittenfeld S, Davicioni E, du Plessis M, Buerki C, Bullen J, Li L, Madabhushi A, Stephenson A, Klein EA. Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. Eur Radiol. 2019 Sep;29(9):4861-4870. doi: 10.1007/s00330-019-06114-x. Epub 2019 Mar 7. PubMed PMID: 30847589; PubMed Central PMCID: PMC6684343.

Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC. Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clin Cancer Res. 2019 Jul 1;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558. Epub 2019 Apr 5. PubMed PMID: 30952638.

Balyimez A, Stephans KL, Abazeed ME, Mian OY. The landscape of early carcinogenesis revealed through the lens of integrative genomics, epigenomics, and transcriptomics. J Thorac Dis. 2019 Jun;11(6):2188-2191. doi: 10.21037/jtd.2019.06.07. PubMed PMID: 31372248; PubMed Central PMCID: PMC6626785.

Abu-Gheida I, Reddy CA, Kotecha R, Weller MA, Shah C, Kupelian PA, Mian O, Ciezki JP, Stephans KL, Tendulkar RD. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):325-333. doi: 10.1016/j.ijrobp.2019.01.091. Epub 2019 Feb 2. PubMed PMID: 30721720.

Yu JB, Beck TF, Anscher MS, Baschnagel AM, Brock KK, Carlson DJ, Dominello MM, Kimple RJ, Knisely JPS, Mendonca MS, Mian OY, Singh AK, Moros EG, Keen JC. The ASTRO Research Portfolio: Where Do We Go From Here?. Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):308-309. doi: 10.1016/j.ijrobp.2018.09.009. PubMed PMID: 30647008.

Yu JB, Beck TF, Anscher MS, Baschnagel AM, Brock KK, Carlson DJ, Dominello MM, Kimple RJ, Knisely JP, Mendonca MS, Mian OY, Singh AK, Moros EG, Keen JC. Analysis of the 2017 American Society for Radiation Oncology (ASTRO) Research Portfolio. Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):297-304. doi: 10.1016/j.ijrobp.2018.07.2056. PubMed PMID: 30647006.

Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clin Cancer Res. 2019 Jan 1;25(1):210-221. doi: 10.1158/1078-0432.CCR-18-1278. Epub 2018 Oct 16. PubMed PMID: 30327311; PubMed Central PMCID: PMC6333466.

2018

Cheng Z, Rosati LM, Chen L, Mian OY, Cao Y, Villafania M, Nakatsugawa M, Moore JA, Robertson SP, Jackson J, Hacker-Prietz A, He J, Wolfgang CL, Weiss MJ, Herman JM, Narang AK, McNutt TR. Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy. Adv Radiat Oncol. 2018 Oct-Dec;3(4):601-610. doi: 10.1016/j.adro.2018.07.002. eCollection 2018 Oct-Dec. PubMed PMID: 30370361; PubMed Central PMCID: PMC6200892.

Dominello MM, Keen JC, Beck TF, Bayouth J, Knisely J, Carlson DJ, Mendonca MS, Mian O, Brock KK, Anscher M, Hugo G, Moros EG, Singh AK, Yu JB. Responses to the 2017 "1 Million Gray Question": ASTRO Membership's Opinions on the Most Important Research Question Facing Radiation Oncology. Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):249-250. doi: 10.1016/j.ijrobp.2018.06.045. Epub 2018 Jul 10. PubMed PMID: 30003995.

Vargas R, Gopal P, Kuzmishin GB, DeBernardo R, Koyfman SA, Jha BK, Mian OY, Scott J, Adams DJ, Peacock CD, Abazeed ME. Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response. NPJ Precis Oncol. 2018;2:14. doi: 10.1038/s41698-018-0060-3. eCollection 2018. PubMed PMID: 30202792; PubMed Central PMCID: PMC6041303.

Bae HJ, Mian O, Vaidya D, DeWeese TL, Song DY. Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy. Pract Radiat Oncol. 2018 May-Jun;8(3):e159-e165. doi: 10.1016/j.prro.2017.10.004. Epub 2017 Oct 10. PubMed PMID: 29153901; PubMed Central PMCID: PMC5893440.

Ferro A, Bae HJ, Yenokyan G, Le Y, McNutt T, Mian O, Gergis C, Haviland C, DeWeese TL, Song DY. Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy. Brachytherapy. 2018 Mar-Apr;17(2):313-318. doi: 10.1016/j.brachy.2017.10.008. Epub 2017 Nov 23. PubMed PMID: 29174937; PubMed Central PMCID: PMC5834355.

2017

Mian OY, Tendulkar RD, Abazeed ME. The evolving role of molecular profiling in prostate cancer: basal and luminal subtyping transcends tissue of origin. Transl Cancer Res. 2017 Dec;6(Suppl 9):S1441-S1445. doi: 10.21037/tcr.2017.10.49. PubMed PMID: 30873354; PubMed Central PMCID: PMC6414213.

Lee J, Mian OY, Le Y, Bae HJ, Burdette EC, DeWeese TL, Prince JL, Song DY. Intraoperative Registered Ultrasound and Fluoroscopy (iRUF) for dose calculation during prostate brachytherapy: Improved accuracy compared to standard ultrasound-based dosimetry. Radiother Oncol. 2017 Jul;124(1):61-67. doi: 10.1016/j.radonc.2017.05.018. Epub 2017 Jun 21. PubMed PMID: 28647400; PubMed Central PMCID: PMC5553286.

2016

Lock M, Malayeri AA, Mian OY, Mayr NA, Herman JM, Lo SS. Computed tomography imaging assessment of postexternal beam radiation changes of the liver. Future Oncol. 2016 Dec;12(23):2729-2739. doi: 10.2217/fon-2016-0165. Epub 2016 Aug 31. Review. PubMed PMID: 27576360; PubMed Central PMCID: PMC5551926.

Mian OY, Thomas O, Lee JJ, Le Y, McNutt T, Lim M, Rigamonti D, Wolinsky JP, Sciubba DM, Gokaslan ZL, Redmond K, Kleinberg L. Timely stereotactic body radiotherapy (SBRT) for spine metastases using a rapidly deployable automated planning algorithm. Springerplus. 2016;5(1):1337. doi: 10.1186/s40064-016-2961-3. eCollection 2016. PubMed PMID: 27563532; PubMed Central PMCID: PMC4981010.

Choflet A, Narang AK, Herald Hoofring L, Bonerigo S, Mian OY, Katulis L, Cheng Z, Appling S. Prevalence of Substance Use in Patients With Cancer Receiving Radiation Therapy. Clin J Oncol Nurs. 2016 Aug 1;20(4):397-402. doi: 10.1188/16.CJON.397-402. PubMed PMID: 27441512.

Hedayati M, Haffner MC, Coulter JB, Raval RR, Zhang Y, Zhou H, Mian O, Knight EJ, Razavi N, Dalrymple S, Isaacs JT, Santos A, Hales R, Nelson WG, Yegnasubramanian S, DeWeese TL. Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation. Clin Cancer Res. 2016 Jul 1;22(13):3310-3319. doi: 10.1158/1078-0432.CCR-15-1147. Epub 2016 Feb 1. PubMed PMID: 26831716; PubMed Central PMCID: PMC4930695.

Mian OY, Khattab MH, Hedayati M, Coulter J, Abubaker-Sharif B, Schwaninger JM, Veeraswamy RK, Brooks JD, Hopkins L, Shinohara DB, Cornblatt B, Nelson WG, Yegnasubramanian S, DeWeese TL. GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. Prostate. 2016 Feb;76(2):199-206. doi: 10.1002/pros.23111. Epub 2015 Oct 8. PubMed PMID: 26447830; PubMed Central PMCID: PMC4734373.

2014

Kuo N, Dehghan E, Deguet A, Mian OY, Le Y, Burdette EC, Fichtinger G, Prince JL, Song DY, Lee J. An image-guidance system for dynamic dose calculation in prostate brachytherapy using ultrasound and fluoroscopy. Med Phys. 2014 Sep;41(9):091712. doi: 10.1118/1.4893761. PubMed PMID: 25186387; PubMed Central PMCID: PMC4149691.

Mian OY, Ram AN, Tuli R, Herman JM. Management options in locally advanced pancreatic cancer. Curr Oncol Rep. 2014 Jun;16(6):388. doi: 10.1007/s11912-014-0388-y. Review. PubMed PMID: 24740136.

2013

Eck P, Kwon O, Chen S, Mian O, Levine M. The human sodium-dependent ascorbic acid transporters SLC23A1 and SLC23A2 do not mediate ascorbic acid release in the proximal renal epithelial cell. Physiol Rep. 2013 Nov;1(6):e00136. doi: 10.1002/phy2.136. Epub 2013 Nov 7. PubMed PMID: 24400138; PubMed Central PMCID: PMC3871451. 

2011

Mian OY, Wang SZ, Zhu SZ, Gnanapragasam MN, Graham L, Bear HD, Ginder GD. Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells. Mol Cancer Res. 2011 Aug;9(8):1152-62. doi: 10.1158/1541-7786.MCR-11-0252. Epub 2011 Jun 21. PubMed PMID: 21693597; PubMed Central PMCID: PMC3157569.

2008

Ginder GD, Gnanapragasam MN, Mian OY. The role of the epigenetic signal, DNA methylation, in gene regulation during erythroid development. Curr Top Dev Biol. 2008;82:85-116. doi: 10.1016/S0070-2153(07)00004-X. Review. PubMed PMID: 18282518. 

2006

Patino WD, Kang JG, Matoba S, Mian OY, Gochuico BR, Hwang PM. Atherosclerotic plaque macrophage transcriptional regulators are expressed in blood and modulated by tristetraprolin. Circ Res. 2006 May 26;98(10):1282-9. doi: 10.1161/01.RES.0000222284.48288.28. Epub 2006 Apr 13. PubMed PMID: 16614304. 

2005

Shizukuda Y, Matoba S, Mian OY, Nguyen T, Hwang PM. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol Cell Biochem. 2005 May;273(1-2):25-32. doi: 10.1007/s11010-005-5905-8. PubMed PMID: 16013437.

Patino WD, Mian OY, Kang JG, Matoba S, Bartlett LD, Holbrook B, Trout HH 3rd, Kozloff L, Hwang PM. Circulating transcriptome reveals markers of atherosclerosis. Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3423-8. doi: 10.1073/pnas.0408032102. Epub 2005 Feb 22. PubMed PMID: 15728378; PubMed Central PMCID: PMC552911. 

2003

Patino WD, Mian OY, Shizukuda Y, Hwang PM. Current and future applications of SAGE to cardiovascular medicine. Trends Cardiovasc Med. 2003 May;13(4):163-8. doi: 10.1016/s1050-1738(03)00055-0. Review. PubMed PMID: 12732451. 

2002

Patino WD, Mian OY, Hwang PM. Serial analysis of gene expression: technical considerations and applications to cardiovascular biology. Circ Res. 2002 Oct 4;91(7):565-9. doi: 10.1161/01.res.0000036018.76903.18. Review. PubMed PMID: 12364383.